MTX-101 is under clinical development by Mozart Therapeutics and currently in Phase I for Celiac Disease. According to GlobalData, Phase I drugs for Celiac Disease does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MTX-101 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MTX-101 overview
MTX-101 is under development for the treatment of type I diabetes, celiac disease and rheumatological diseases. The therapeutic candidate is a bispecific CD8 Treg modulator targeting inhibitory KIR2DL1/2/3 and regulatory CD8 T cell specific markers. It is administered through intravenous route.
Mozart Therapeutics overview
Mozart Therapeutics is a biopharmaceutical company that discovers, develops and commercializes treatments for autoimmune and inflammatory diseases. Its pipeline products include MTX-101, for early stage and slowly-progressing autoimmune diseases, such as type 1 diabetes mellitus and celiac disease; and MTX-201, for the treatment of highly inflammatory autoimmune diseases, such as inflammatory bowel diseases. Mozart Therapeutics’ CD8 Treg cell modulators to treat celiac disease, a digestive and autoimmune disorder that damages small intestine; inflammatory bowel disease (IBD); and other autoimmune disorders. The company operates in the US. Mozart Therapeutics is headquartered in Seattle, Washington, the US.
For a complete picture of MTX-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
